DOJ wants Anthem-Cigna bickering made public

The U.S. Justice Department (DOJ) may have new ammunition in their fight to keep Anthem and Cigna from merging: the companies’ own behind-the-scenes bickering.

The New York Times reported on a legal filing from the DOJ that alleges the in-house attorneys for both companies have exchanged letters accusing the other of violating the terms of the $48 million merger agreement. The DOJ is asking a federal judge to compel the insurers to release the letter, arguing they would “reveal the current state of hostility between defendants,” and call into question the insurers’ claims that the merger would save billions of dollars and improve care.  

“Such efficiencies don’t happen overnight,” the DOJ wrote in its court filing according to the Times. “They require cooperation over months (if not years) to integrate the operations of these multibillion-dollar firms.”

Both Anthem and Cigna declined to comment on the filing, though bickering between the insurers had been reported well before the DOJ sued to block the merger on antitrust grounds.

Anthem’s lawyers have hinted at the tension in court, saying a speedier trial schedule was needed, or else Cigna would exercise its right to back out of the merger beginning on April 30, 2017, collecting a $1.85 billion break-up fee in the process.

For more on DOJ’s filing and how the insurers’ disagreements could undermine their defense in the antitrust trial, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup